Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential fibrinolysis with mutant pro-urokinase and low-dose alteplase before primary PCI in STEMI
ISRCTN14164179Phase 2Terminated
- Sponsor
- Thrombolytic Science International
- Start
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes, Therapeutic Enzymes → Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, open-label trial of mutant pro-urokinase and tissue-plasminogen activator in myocardial infarction (MI) (2 arms), sponsored by Thrombolytic Science International. Started Oct 2024; status: terminated.
02
Drugs
mutant pro-urokinasetissue-plasminogen activator
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on ISRCTN14164179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN14164179.